Skip to main content
. 2020 Sep 4;12(9):2519. doi: 10.3390/cancers12092519

Figure 3.

Figure 3

KM plots by test classification of overall and progression-free survival for all patients (n = 121), younger patients (n = 38), and older patients (n = 83) with advanced-stage high-grade serous ovarian carcinoma in the development cohort. The number of patients at risk in the KM analysis at two-year intervals in each test classification group (green = good, and purple = poor) is shown below the x-axis.